Compare STRIDES PHARMA SCIENCE with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PIRAMAL ENTERPRISES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PIRAMAL ENTERPRISES STRIDES PHARMA SCIENCE/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.8 17.6 84.0% View Chart
P/BV x 0.9 1.1 78.2% View Chart
Dividend Yield % 0.6 1.6 35.1%  

Financials

 STRIDES PHARMA SCIENCE   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PIRAMAL ENTERPRISES
Mar-19
STRIDES PHARMA SCIENCE/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1473,303 34.7%   
Low Rs6421,797 35.7%   
Sales per share (Unadj.) Rs317.2716.5 44.3%  
Earnings per share (Unadj.) Rs7.879.7 9.8%  
Cash flow per share (Unadj.) Rs25.1107.9 23.2%  
Dividends per share (Unadj.) Rs2.0028.00 7.1%  
Dividend yield (eoy) %0.21.1 20.4%  
Book value per share (Unadj.) Rs274.31,477.5 18.6%  
Shares outstanding (eoy) m89.50184.45 48.5%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.83.6 79.2%   
Avg P/E ratio x114.032.0 356.4%  
P/CF ratio (eoy) x35.723.6 151.1%  
Price / Book Value ratio x3.31.7 189.0%  
Dividend payout %25.535.1 72.6%   
Avg Mkt Cap Rs m80,058470,292 17.0%   
No. of employees `0002.57.8 32.1%   
Total wages/salary Rs m4,34122,504 19.3%   
Avg. sales/employee Rs Th11,325.816,899.4 67.0%   
Avg. wages/employee Rs Th1,731.42,877.7 60.2%   
Avg. net profit/employee Rs Th280.11,879.9 14.9%   
INCOME DATA
Net Sales Rs m28,394132,153 21.5%  
Other income Rs m9413,128 30.1%   
Total revenues Rs m29,334135,281 21.7%   
Gross profit Rs m3,96566,290 6.0%  
Depreciation Rs m1,5405,202 29.6%   
Interest Rs m1,96244,097 4.5%   
Profit before tax Rs m1,40320,119 7.0%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m978,611 1.1%   
Profit after tax Rs m70214,701 4.8%  
Gross profit margin %14.050.2 27.8%  
Effective tax rate %6.942.8 16.2%   
Net profit margin %2.511.1 22.2%  
BALANCE SHEET DATA
Current assets Rs m24,836122,742 20.2%   
Current liabilities Rs m18,993310,810 6.1%   
Net working cap to sales %20.6-142.3 -14.5%  
Current ratio x1.30.4 331.1%  
Inventory Days Days7123 307.7%  
Debtors Days Days11339 292.0%  
Net fixed assets Rs m34,289116,904 29.3%   
Share capital Rs m895369 242.6%   
"Free" reserves Rs m23,651272,161 8.7%   
Net worth Rs m24,546272,530 9.0%   
Long term debt Rs m15,513270,196 5.7%   
Total assets Rs m65,437856,261 7.6%  
Interest coverage x1.71.5 117.8%   
Debt to equity ratio x0.61.0 63.7%  
Sales to assets ratio x0.40.2 281.1%   
Return on assets %4.16.9 59.3%  
Return on equity %2.95.4 53.0%  
Return on capital %6.912.4 55.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69715,200 103.3%   
Fx outflow Rs m7354,889 15.0%   
Net fx Rs m14,96210,312 145.1%   
CASH FLOW
From Operations Rs m1,871-115,975 -1.6%  
From Investments Rs m5,826-8,265 -70.5%  
From Financial Activity Rs m-10,157107,525 -9.4%  
Net Cashflow Rs m-2,615-16,650 15.7%  

Share Holding

Indian Promoters % 27.7 52.9 52.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.0 945.0%  
FIIs % 8.6 26.6 32.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 16.5 157.0%  
Shareholders   56,241 93,274 60.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 19, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS